Login

Eli Lilly raises cost of planned US manufacturing expansion to $50 billion

Pharmaceutical company to increase manufacturing in US amid tariff threats
Eli Lilly & Co.'s real estate portfolio includes this Indianapolis research lab. (CoStar)
Eli Lilly & Co.'s real estate portfolio includes this Indianapolis research lab. (CoStar)
CoStar News
February 26, 2025 | 11:17 P.M.

Pharmaceutical giant Eli Lilly & Co. said it's on the hunt for American industrial sites as it boosts the scope of its manufacturing expansion program to $50 billion after President Donald Trump’s recent threat to implement tariffs on products including drugs.

This news story is available exclusively to CoStar subscribers.

Watch the video to learn how you can access industry leading CRE news and the data analytics you need to drive success.

This news story is available exclusively to CoStar subscribers.

Ready to Learn More?

Sign Up For a Personalized Demo.

Sign Up For a Demo To Learn More.

Already A Subscriber? Sign In

IN THIS ARTICLE